Friday 21st June to Saturday 22nd June 2019 in Dublin
Day 1 | Friday 21st June 2019 | |
13:00-13:30 | Arrivals and Registration | |
13.30-13.45 | Welcome and Opening | |
13.45-15.00 |
SESSION 1: HOT TOPICS IN HIV: PHYSICIAN AND PATIENT PERSPECTIVEOverview of HIV Therapy & Novel Approaches – Prof William Powderly, Washington University in St Louis, US Community Perspective on New Research Developments – Mr Simon Collins, European AIDS Treatment Group (EATG) |
|
15.00-15.15 | Coffee Break | |
15.15-16.45 |
SESSION 2: HOST-PATHOGEN INTERFACEUnraveling the Immune Mechanisms Behind Co-morbidities in HIV: Insights from the Immuno-skeletal Interface – Dr Tara McGinty, University College Dublin, Ireland Molecular Control of HIV-1 Latency: What Can We Learn from the Brain Reservoirs? – Prof Olivier Rohr, University of Strasbourg, France Intact HIV Reservoir and Viral Decay: Are We Measuring It Right? – Prof Giuseppe Nunnari, University of Messina, Italy |
|
16.45-17:00 | Questions & Debate |
Day 2 | Saturday 22nd June 2019 | |
09.00-09.30 | Arrivals, Registration and Breakfast | |
9.30-11.15 |
SESSION 3: LIVING SUCCESSFULLY WITH HIV: MULTIDISCIPLINARY APPROACHThe Measure of Success in Aging with HIV – Prof Giovanni Guaraldi, University of Modena and Reggio Emilia, Italy ‘1 in 4’: The Female HIV Experience, Insights from Research – Dr Denise Proudfoot, Dublin City University, Ireland Patient’s Role in HIV Research and Care Delivery – Mr Robbie Lawlor, Dublin City University, Ireland |
|
11.15-11.30 | Coffee Break | |
11.30-12.45 |
SESSION 4: HIV AND TB: GLOBAL BEDFELLOWSHIV, TB and MAC in Europe: an Emerging Threat – Dr Gregory Kaminskiy, National Medical Research Centre of Phthisiopulmonology and Infectious Diseases, Russian Federation Whole Genome Sequencing for Tuberculosis Treatment and Control: A Game Changer? – Dr Iñaki Comas, Biomedicine Institute of Valencia, CSIC, Spain |
|
12.45-13.00 | Summary and Meeting Close |
Email: europeanhivseminars@ucd.ie
Twitter: @HIVMRG
This meeting is supported by educational grants from ViiV Healthcare, Gilead Sciences, Merck Sharp & Dohme and Janssen Sciences Ireland which have taken no role in designing the agenda or educational content of the meeting